LEO Pharma has reported outcomes from the 16-week interim analysis of the Phase IIIb ADHAND trial of tralokinumab for hand atopic dermatitis (AD).

The trial aims to assess the safety and efficacy of tralokinumab 300mg administered biweekly as a single agent.

[A]lthough our findings found that there is insufficient evidence to suggest that dupilumab use is associated with joint pain, the prevalence of joint pain observed among patients treated with ...

Promising Psoriasis Pipeline Therapies such as Hypericin, EDP1815, Cetaphil, AX-158, HAT1 topical solution, Calcipotriol, ARQ ...

The best shower temperature for your health depends on your goals. Experts recommend showering in lukewarm water, but there ...

Amgen has transitioned into a mature, cash-generating pharma-biotech hybrid. Click here to find out why AMGN stock is a Buy.

Treatment with dupilumab is associated with weight gain in about two thirds of adults with atopic dermatitis over 3-6 months, according to a retrospective study.

Young patients with atopic dermatitis prioritize different treatment goals and have varying preferences from their caregivers.

Merck & Co., Inc. is acquiring Verona Pharma plc for $10bn to bolster long-term growth with COPD drug Ohtuvayre. Click for my ...

An extended day in the sun can be anything but relaxing for those who develop polymorphous light eruption, an uncomfortable, ...

"I had been pretty healthy," Nicole said. "So, to find out that I got this, I thought, well I'm so healthy, I don't know, ...